Literature DB >> 18492761

Circulating ghrelin, leptin, and soluble leptin receptor concentrations and cardiometabolic risk factors in a community-based sample.

Erik Ingelsson1, Martin G Larson, Xiaoyan Yin, Thomas J Wang, James B Meigs, Izabella Lipinska, Emelia J Benjamin, John F Keaney, Ramachandran S Vasan.   

Abstract

CONTEXT: The conjoint effects and relative importance of ghrelin, leptin, and soluble leptin receptor (sOB-R), adipokines involved in appetite control and energy expenditure in mediating cardiometabolic risk, is unknown.
OBJECTIVE: The objective of the study was to study the cross-sectional relations of these adipokines to cardiometabolic risk factors in a community-based sample. DESIGN, SETTING, AND PARTICIPANTS: We measured circulating ghrelin, leptin, and sOB-R in 362 participants (mean age 45 yr; 54% women) of the Framingham Third Generation Cohort. MAIN OUTCOME MEASURES: Body mass index, waist circumference (WC), blood pressure, lipid measures, fasting glucose, smoking, and metabolic syndrome (MetS) were measured.
RESULTS: Ghrelin and leptin concentrations were significantly higher in women (P < 0.0001). In multivariable models, ghrelin was inversely associated with age and systolic blood pressure, and leptin was positively related to body mass index and WC. sOB-R was positively associated with age, total cholesterol, and fasting glucose and inversely with WC and high-density lipoprotein cholesterol. Ghrelin and sOB-R concentrations were significantly lower with number of MetS components (P for trend = 0.022 and < 0.0001, respectively), whereas leptin concentrations were higher (P for trend = 0.0001). Relating all adipokines to MetS conjointly, higher ghrelin and leptin concentrations were associated with decreased and increased odds of MetS (odds ratio 0.55, P < 0.0001; odds ratio 4.44, P = 0.0002, per 1 sd increase of respective log adipokine).
CONCLUSIONS: In our community-based sample, we observed a sexual dimorphism in circulating ghrelin and leptin concentrations. Ghrelin, leptin, and sOB-R were associated with number of MetS components cross-sectionally, consistent with the hypothesis that these adipokines may have a central role in cardiometabolic risk.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18492761      PMCID: PMC2515078          DOI: 10.1210/jc.2008-0207

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  45 in total

1.  Circulating peptide YY concentrations are higher in preterm than full-term infants and correlate negatively with body weight and positively with serum ghrelin concentrations.

Authors:  Tania Siahanidou; Helen Mandyla; Maria Vounatsou; Dimitris Anagnostakis; Ioannis Papassotiriou; George P Chrousos
Journal:  Clin Chem       Date:  2005-09-09       Impact factor: 8.327

2.  Serum leptin concentration, obesity, and insulin resistance in Western Samoans: cross sectional study.

Authors:  P Zimmet; A Hodge; M Nicolson; M Staten; M de Courten; J Moore; A Morawiecki; J Lubina; G Collier; G Alberti; G Dowse
Journal:  BMJ       Date:  1996-10-19

3.  Effects of gender, body composition, and menopause on plasma concentrations of leptin.

Authors:  M Rosenbaum; M Nicolson; J Hirsch; S B Heymsfield; D Gallagher; F Chu; R L Leibel
Journal:  J Clin Endocrinol Metab       Date:  1996-09       Impact factor: 5.958

4.  Leptin predicts a worsening of the features of the metabolic syndrome independently of obesity.

Authors:  Paul W Franks; Soren Brage; Jian'an Luan; Ulf Ekelund; Mushtaquar Rahman; I Sadaf Farooqi; Ian Halsall; Stephen O'Rahilly; Nicholas J Wareham
Journal:  Obes Res       Date:  2005-08

5.  Circulating levels of active ghrelin is associated with abdominal adiposity, hyperinsulinemia and insulin resistance in patients with type 2 diabetes mellitus.

Authors:  Akira Katsuki; Hideki Urakawa; Esteban C Gabazza; Shuichi Murashima; Kaname Nakatani; Kenji Togashi; Yutaka Yano; Yukihiko Adachi; Yasuhiro Sumida
Journal:  Eur J Endocrinol       Date:  2004-11       Impact factor: 6.664

6.  UKPDS 20: plasma leptin, obesity, and plasma insulin in type 2 diabetic subjects.

Authors:  A Widjaja; I M Stratton; R Horn; R R Holman; R Turner; G Brabant
Journal:  J Clin Endocrinol Metab       Date:  1997-02       Impact factor: 5.958

7.  Low plasma ghrelin is associated with insulin resistance, hypertension, and the prevalence of type 2 diabetes.

Authors:  Seppo M Pöykkö; Eija Kellokoski; Sohvi Hörkkö; Heikki Kauma; Y Antero Kesäniemi; Olavi Ukkola
Journal:  Diabetes       Date:  2003-10       Impact factor: 9.461

8.  The associations between plasma adiponectin, ghrelin levels and cardiovascular risk factors.

Authors:  K M Choi; J Lee; K W Lee; J A Seo; J H Oh; S G Kim; N H Kim; D S Choi; S H Baik
Journal:  Eur J Endocrinol       Date:  2004-05       Impact factor: 6.664

9.  Hyperleptinemia as a component of a metabolic syndrome of cardiovascular risk.

Authors:  F Leyva; I F Godsland; M Ghatei; A J Proudler; S Aldis; C Walton; S Bloom; J C Stevenson
Journal:  Arterioscler Thromb Vasc Biol       Date:  1998-06       Impact factor: 8.311

10.  Relationships between serum soluble leptin receptor level and serum leptin and adiponectin levels, insulin resistance index, lipid profile, and leptin receptor gene polymorphisms in the Japanese population.

Authors:  Takeo Ogawa; Hiroshi Hirose; Yukihiro Yamamoto; Kanako Nishikai; Kiichi Miyashita; Haruo Nakamura; Ikuo Saito; Takao Saruta
Journal:  Metabolism       Date:  2004-07       Impact factor: 8.694

View more
  27 in total

1.  Longitudinal changes in adipokines and free leptin index during and after pregnancy in women with obesity.

Authors:  Ulrika Andersson-Hall; Pernilla Svedin; Henrik Svensson; Malin Lönn; Carina Mallard; Agneta Holmäng
Journal:  Int J Obes (Lond)       Date:  2019-09-24       Impact factor: 5.095

2.  A comparison between metabolic syndrome post-hematopoietic stem cell transplantation and spontaneously occurring metabolic syndrome.

Authors:  L Airaghi; P Usardi; S Forti; A Orsatti; M Baldini; C Annaloro; G Lambertenghi Deliliers
Journal:  J Endocrinol Invest       Date:  2010-07-01       Impact factor: 4.256

Review 3.  Stress and immunosenescence: The role of telomerase.

Authors:  Karin de Punder; Christine Heim; Pathik D Wadhwa; Sonja Entringer
Journal:  Psychoneuroendocrinology       Date:  2018-10-23       Impact factor: 4.905

4.  Ghrelin levels in chronic periodontitis patients.

Authors:  Gülin Yılmaz; Fatma Yeşim Kırzıoğlu; Duygu Kumbul Doğuç; Havva Koçak; Hikmet Orhan
Journal:  Odontology       Date:  2013-01-05       Impact factor: 2.634

5.  Circulating Adipokines and Vascular Function: Cross-Sectional Associations in a Community-Based Cohort.

Authors:  Justin P Zachariah; Susan Hwang; Naomi M Hamburg; Emelia J Benjamin; Martin G Larson; Daniel Levy; Joseph A Vita; Lisa M Sullivan; Gary F Mitchell; Ramachandran S Vasan
Journal:  Hypertension       Date:  2015-11-30       Impact factor: 10.190

6.  Stress does not affect ghrelin secretion in obese and normal weight women.

Authors:  Gundula R R Kiessl; Reinhold G Laessle
Journal:  Eat Weight Disord       Date:  2016-08-29       Impact factor: 4.652

Review 7.  Adipocytokines in atherothrombosis: focus on platelets and vascular smooth muscle cells.

Authors:  Giovanni Anfossi; Isabella Russo; Gabriella Doronzo; Alice Pomero; Mariella Trovati
Journal:  Mediators Inflamm       Date:  2010-06-28       Impact factor: 4.711

8.  Integrating GHS into the Ghrelin System.

Authors:  Johannes D Veldhuis; Cyril Y Bowers
Journal:  Int J Pept       Date:  2010-03-18

9.  Insulinlike Growth Factor Binding Protein-1 and Ghrelin Predict Health Outcomes Among Older Adults: Cardiovascular Health Study Cohort.

Authors:  Robert C Kaplan; Garrett Strizich; Chino Aneke-Nash; Clara Dominguez-Islas; Petra Bužková; Howard Strickler; Thomas Rohan; Michael Pollak; Lewis Kuller; Jorge R Kizer; Anne Cappola; Christopher I Li; Bruce M Psaty; Anne Newman
Journal:  J Clin Endocrinol Metab       Date:  2017-01-01       Impact factor: 5.958

Review 10.  AMP-activated protein kinase pathway: a potential therapeutic target in cardiometabolic disease.

Authors:  Aaron K F Wong; Jacqueline Howie; John R Petrie; Chim C Lang
Journal:  Clin Sci (Lond)       Date:  2009-04       Impact factor: 6.124

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.